Melatoninergic System in Parkinson’s Disease: From Neuroprotection to the Management of Motor and Nonmotor Symptoms

Table 1

Drugs used for symptomatic treatment of Parkinson’s disease.

Drug	Mechanism of action
L-DOPA	DA precursor
L-DOPA + benserazide or carbidopa	DA precursor + peripheral dopa-decarboxylase inhibitor
Bromocriptine, pergolide, pramipexole, ropinirole	DA receptor agonists
Selegiline, rasagiline	Monoamine oxidase B inhibitors
Amantadine	Increase of DA release and glutamate NMDA receptor antagonist
Trihexyphenidyl, benztropine	Muscarinic receptor antagonists
Entacapone, tolcapone	Catechol-O-methyltransferase inhibitors

Adapted from [108].